Pieris Pharmaceuticals (PIRS) Peer Comparison

$13.26

$-2.87 (-17.79%)

As on 13-Dec-2024 16:03EDT

Market cap

$21 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

--

P/B Ratio

1.1

Div. Yield

0 %

Edit

	Pieris Pharmaceuticals (PIRS)	Longboard Pharmaceuticals (LBPH)	Lumos Pharma (LUMO)
Market cap ($ Mln)	21	2,342	38
Revenue ($ Mln)	1	0	2
Net Profit ($ Mln)	-15.95	-76.34	-34.92
Net Margin (%)	-1,179.96	-954,300.00	-1,583.49
RoE (%)	-83.45	-25.93	-312.41
Price to Earnings	--	--	--
Price-To-Book	1.10	8.51	7.64

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Pieris Pharmaceuticals (PIRS)	Longboard Pharmaceuticals (LBPH)	Lumos Pharma (LUMO)
Operating Revenue	42.81	0.00	2.05
Cost of Revenue	41.80	0.01	0.04
Gross Profit	1.01	-0.01	2.05
Operating Expenses	72.57	56.76	38.67
Operating Profit (EBIT)	-29.76	-56.76	-36.61
Other Income	--	-0.53	--
Profit before Tax	-24.54	-54.42	-34.06
Provision for Tax	13.91	-0.85	-0.03
Profit after Tax (Net Income)	-24.54	-54.42	-34.03
Minority Interest	--	--	--
Consolidated Profit	--	-43.95	-31.06

Liabilities ($ Mln)

	Pieris Pharmaceuticals (PIRS)	Longboard Pharmaceuticals (LBPH)	Lumos Pharma (LUMO)
Shareholder's Funds	26.76	40.92	27.31
Minority Interest	--	--	--
Non-Current Liabilities	30.98	0.00	6.30
Current Liabilities	11.92	9.77	7.03
Total Liabilities	38.68	50.70	40.64

Assets ($ Mln)

	Pieris Pharmaceuticals (PIRS)	Longboard Pharmaceuticals (LBPH)	Lumos Pharma (LUMO)
Non-Current Assets	22.07	0.48	0.60
Current Assets	38.68	50.22	40.04
Total Assets	38.68	50.70	40.64
Total Debt*	13.10	0.48	0.59
Net Current Assets	36.84	40.45	33.01

Cashflow ($ Mln)

	Pieris Pharmaceuticals (PIRS)	Longboard Pharmaceuticals (LBPH)	Lumos Pharma (LUMO)
Cash From Operating Activities	-53.82	-50.87	-31.10
Cash Flow from Investing Activities	--	-17.06	-11.36
Cash from Financing Activities	19.80	30.19	-0.58
Net Cash Inflow / Outflow	--	-55.57	--

Ratios

Profitability Ratios

	Pieris Pharmaceuticals (PIRS)	Longboard Pharmaceuticals (LBPH)	Lumos Pharma (LUMO)
ROCE (%)	-72.41	-105.05	-77.61
ROE (%)	-89.76	-106.30	-78.34
ROA (%)	-36.58	-89.72	-60.27
EBIT Margin (%)	--	--	--
Net Margin (%)	-57.33	8,161.36	-1,659.39
Cash Profit Margin (%)	--	--	--

Growth Ratios

	Pieris Pharmaceuticals (PIRS)	Longboard Pharmaceuticals (LBPH)	Lumos Pharma (LUMO)
Revenue Growth (%)	0.65	--	0.35
EBIT Growth (%)	--	--	--
Net Profit Growth (%)	21.47	-26.29	-9.57
EPS Growth (%)	--	0.09	-0.12
Book Value Growth (%)	--	--	--

Valuation Ratios

	Pieris Pharmaceuticals (PIRS)	Longboard Pharmaceuticals (LBPH)	Lumos Pharma (LUMO)
Price / Earnings	--	-2.65	-0.76
Price / Book Value	--	3.53	0.94
Dividend Yield (%)	--	--	--
EV/EBITDA	1.16	-1.70	0.27
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	Pieris Pharmaceuticals (PIRS)	Longboard Pharmaceuticals (LBPH)	Lumos Pharma (LUMO)
Debt to Equity	0.47	0.01	0.02
Short term debt to equity ratio	0.03	0.01	0.02
Current Ratio	3.24	5.14	5.69
Quick Ratio	2.90	--	--
Interest Coverage	-3.26	-53.52	-36.66

Operating Efficiency Ratios

	Pieris Pharmaceuticals (PIRS)	Longboard Pharmaceuticals (LBPH)	Lumos Pharma (LUMO)
Debtors to sales (%)	1.34	--	10.24
Asset Turnover	0.64	0.00	0.04
Receivable days	27.23	--	38.56
Inventory Days	35.71	--	-954.12
Payable days	32.88	84,409.28	4,835.41
Cash Conversion Cycle	30.06	--	-4,217.92

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly